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156 Validation in extended pedigrees 157 We selected the top 10 RA candidate variants, with the strongest association with RA, for re-158 sequencing to confirm their family specificity and their co-segregation with RA (Table 4 ). We 159 analyzed further 9 out of 10 variants for which we were able to produce sequences and, we 160 validated the familial specificity for all of them. Five variants (in SUPT20H, NOLC1, GXYLT2, 161 MAP4 and STC2 genes) were shared by all affected members in the families who carried these 162 variants. However, only one candidate variant showed a complete segregation with RA. This 163 variant is a heterozygous non-sense SNV, c.73T>A (p.Lys25*), located in SUPT20H gene which 164 introduces a premature codon stop at the beginning of the gene (in the fourth exon) (Fig 3) .
165 This variant, not reported to date, has been deposited in ClinVar database prior to publication.
166 168 Genotyping of SNV c.73T>A (p.Lys25*) in family 3 and in trios 169 The SNV c.73T>A (p.Lys25*) carried by SUPT20H was genotyped using a custom assay and 170 digital PCR. First, genotyping results in family 3 validated the presence of the rare A allele in 171 affected members of the family and, its absence in unaffected members (Fig 4) . Second, we 172 investigated 188 RA patients (characteristics described in supplementary Table S1 ) and 362 173 healthy parents from trio families using one affected member of family 3 as a positive control.
174 No one of these samples showed the rare allele of this SNV. 293 mapping quality MQ < 30, variant confidence QD < 2 and strand bias FS score > 25. We 294 annotated genotypes with an individual DP < 10 as missing before filtering out variants with 295 call-rate < 95% with Plink1.9 [39] . Finally, we removed variants located in segmental 296 duplications [40] and repeated regions, such as described in RepeatMasker from UCSC [41] .
Variant annotation and classification
298 We classified the remaining variants into rare variants (MAF < 1%), low frequency variants 299 (1% ≤ MAF < 5%) and common variants (MAF ≥ 5%) according to their frequency in public 300 databases. To evaluate these frequencies, we worked on 4 datasets extracted from: (1) 305 To investigate the predicted effect of the genetic variants on proteins, we annotated them 306 with CADD phred-like score [42] using ANNOVAR [43] and with variant effect defined in SNPeff 307 [44] . The former is a score obtained from a model trained to separate evolutionary conserved 308 variants, likely deleterious, from simulated variants, likely benign. And the latter evaluate the 309 putative variant impact at the transcript level by using sequence ontology.
310 Principal Component Analysis of CEU controls and discovery set 311 To identify possible genetic population stratification between the discovery set and the 45 312 CEU controls, we performed a principal component analysis (PCA). For this analysis, we used 313 a subset of variants located on autosomes classified as neutrals and frequents. We defined as 314 neutral a variant annotated "LOW" by SNPEff and with a CADD phred-like score < 5. Those The PCA is based on the 30 samples from the discovery set and 45 CEU controls extracted from the 1000 genomes databases. This plot represents the 2 first principal components which respectively account for 3.59% and 3.09% of the genetic variability. The color code represents the population source: each family sequenced by WES has its own color described in the legend, the CEU controls are in grey. The shape of each dot represents the RA status of the represented individual. 
